Intervention Review

Naftopidil for the treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia

  1. Pranav S. Garimella2,
  2. Howard A Fink3,
  3. Roderick MacDonald1,
  4. Timothy J Wilt1,*

Editorial Group: Cochrane Prostatic Diseases and Urologic Cancers Group

Published Online: 7 OCT 2009

Assessed as up-to-date: 15 JUN 2009

DOI: 10.1002/14651858.CD007360.pub2

How to Cite

Garimella PS, Fink HA, MacDonald R, Wilt TJ. Naftopidil for the treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia. Cochrane Database of Systematic Reviews 2009, Issue 4. Art. No.: CD007360. DOI: 10.1002/14651858.CD007360.pub2.

Author Information

  1. 1

    VAMC, General Internal Medicine (111-0), Minneapolis, Minnesota, USA

  2. 2

    John H. Stroger Hospital of Cook County, Chicago, Illinois, USA

  3. 3

    VA Medical Center, Geriatric Research Education and Clinical Center, Box 11G, Minneapolis, Minnesota, USA

*Timothy J Wilt, General Internal Medicine (111-0), VAMC, One Veterans Drive, Minneapolis, Minnesota, 55417, USA. Tim.Wilt@med.va.gov.

Publication History

  1. Publication Status: Edited (no change to conclusions)
  2. Published Online: 7 OCT 2009

SEARCH

  1. Current Version

    Naftopidil for the treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia

    Pranav S. Garimella, Howard A Fink, Roderick MacDonald and Timothy J Wilt

    Article first published online: 7 OCT 2009 | DOI: 10.1002/14651858.CD007360.pub2

Previous versions of this article and their online publication dates

  1. Version 1

    Naftopidil for the treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia

    Pranav Garimella, Timothy Wilt and Roderick MacDonald

    Article first published online: 8 OCT 2008 | DOI: 10.1002/14651858.CD007360